Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Prices Public Stock Offering

NEW YORK (GenomeWeb News) – Luminex today announced that its public offering of 3.5 million shares of common stock, which is expected to close on June 30, will price at $19.91 per share.
 
The Austin, Texas-based firm expects to realize net proceeds of $64.5 million from the offering. It also has granted underwriters a 30-day option to acquire an additional 525,000 shares of common stock to cover any over-allotments.
 
JPMorgan and UBS are joint book-running managers for the offering, with Avondale Partners, Canaccord Adams, Leerink Swann acting as co-managers.
 
Luminex said in its preliminary prospectus for the offering that net proceeds will be used for general corporate purposes, including research and development, potential acquisitions of, or investments in, companies and technologies, capital expenditures, and additions to working capital.
 
In early Wednesday trade on the Nasdaq, shares of Luminex rose 6.6 percent to $21.22.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.